EAM
PGNX

Eagle Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Eagle Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,506,284
Closed -$22.9M – 683
2019
Q4 		$22.9M Buy
4,506,284
+2,190
+0% +$11.6K 0.11% 222
2019
Q3 		$22.8M Buy
4,504,094
+4,386
+0.1% +$21.9K 0.12% 220
2019
Q2 		$27.8M Sell
4,499,708
-8,722
-0.2% -$42.1K 0.14% 210
2019
Q1 		$20.9M Buy
4,508,430
+13,065
+0.3% +$59.1K 0.11% 222
2018
Q4 		$18.9M Buy
4,495,365
+50,692
+1% +$258K 0.12% 217
2018
Q3 		$27.9M Sell
4,444,673
-16,809
-0.4% -$129K 0.13% 221
2018
Q2 		$35.9M Sell
4,461,482
-9,356
-0.2% -$71.4K 0.19% 189
2018
Q1 		$33.4M Buy
4,470,838
+310,078
+7% +$2.06M 0.18% 186
2017
Q4 		$24.6M Sell
4,160,760
-6,159
-0.1% -$37.4K 0.14% 224
2017
Q3 		$32.2M Buy
4,166,919
+154,553
+4% +$982K 0.18% 191
2017
Q2 		$27.2M Buy
4,012,366
+1,352,245
+51% +$9.98M 0.16% 205
2017
Q1 		$25.1M Sell
2,660,121
-5,143
-0.2% -$51.3K 0.16% 194
2016
Q4 		$23M Buy
+2,665,264
New +$19.7M 0.15% 201

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Eagle Asset Management's PGNX Position: Q1 2020 in Review

Eagle Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 4,506,284 shares — an estimated $22.9M sold.

Eagle Asset Management first reported a position in PGNX in Q4 2016 and held it in 13 quarters. The position peaked at $35.9M in Q2 2018. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • Eagle Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • Eagle Asset Management sold 4,506,284 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $22.9M.
  • Eagle Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q4 2016 and held it in 13 quarters.
  • Eagle Asset Management's Progenics Pharmaceuticals Inc position peaked at $35.9M in Q2 2018.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on Eagle Asset Management's 13F filing for Q1 2020, filed 11 May 2020.